CN104619687A - 能够调节t-细胞应答的双环杂环及其使用方法 - Google Patents
能够调节t-细胞应答的双环杂环及其使用方法 Download PDFInfo
- Publication number
- CN104619687A CN104619687A CN201380033704.2A CN201380033704A CN104619687A CN 104619687 A CN104619687 A CN 104619687A CN 201380033704 A CN201380033704 A CN 201380033704A CN 104619687 A CN104619687 A CN 104619687A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- cycloalkyl
- phenyl
- substituting group
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*C(*)(C(C*)(C(**)(C1=NN(C(*)(*)C(C)(*)I)C2=CI(*C)=C=CC=C12)N)N)N(*)* Chemical compound C*C(*)(C(C*)(C(**)(C1=NN(C(*)(*)C(C)(*)I)C2=CI(*C)=C=CC=C12)N)N)N(*)* 0.000 description 6
- WHRBVTHBWRNJHC-UHFFFAOYSA-N C(CSc1n[n](COc2ccccc2)c2ccccc12)N1CCCCC1 Chemical compound C(CSc1n[n](COc2ccccc2)c2ccccc12)N1CCCCC1 WHRBVTHBWRNJHC-UHFFFAOYSA-N 0.000 description 1
- WAOHRZTULBDWFW-UHFFFAOYSA-N CCC(CC)CCN(c(cccc1)c1N1CC(C2(CC3CC4C5)CC34C5C2)=O)C1=N Chemical compound CCC(CC)CCN(c(cccc1)c1N1CC(C2(CC3CC4C5)CC34C5C2)=O)C1=N WAOHRZTULBDWFW-UHFFFAOYSA-N 0.000 description 1
- ZNDHXGBKPXTIOY-UHFFFAOYSA-N CN(C)CCN(c(cccc1)c1N1CC(C2CCCCC2)=O)C1=N Chemical compound CN(C)CCN(c(cccc1)c1N1CC(C2CCCCC2)=O)C1=N ZNDHXGBKPXTIOY-UHFFFAOYSA-N 0.000 description 1
- BINKLIHBAHPSEH-UHFFFAOYSA-N Cc1cc(C(CNc2ccccc2C(SCN2CCCCC2)=N)=O)c(C)cc1 Chemical compound Cc1cc(C(CNc2ccccc2C(SCN2CCCCC2)=N)=O)c(C)cc1 BINKLIHBAHPSEH-UHFFFAOYSA-N 0.000 description 1
- VWLNFDNUKVHEFP-UHFFFAOYSA-N N=C1N(C2(CC(C3)C4)CC4CC3C2)c2ccccc2N1CCN1CCCCC1 Chemical compound N=C1N(C2(CC(C3)C4)CC4CC3C2)c2ccccc2N1CCN1CCCCC1 VWLNFDNUKVHEFP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261654398P | 2012-06-01 | 2012-06-01 | |
| US61/654,398 | 2012-06-01 | ||
| PCT/EP2013/061328 WO2013178815A1 (en) | 2012-06-01 | 2013-05-31 | Bicyclic heterocycles capable of modulating t-cell responses, and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104619687A true CN104619687A (zh) | 2015-05-13 |
Family
ID=48538005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380033704.2A Pending CN104619687A (zh) | 2012-06-01 | 2013-05-31 | 能够调节t-细胞应答的双环杂环及其使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150126553A1 (https=) |
| EP (1) | EP2861563B1 (https=) |
| JP (1) | JP2015521195A (https=) |
| KR (1) | KR20150016377A (https=) |
| CN (1) | CN104619687A (https=) |
| AU (1) | AU2013269550A1 (https=) |
| BR (1) | BR112014030039A2 (https=) |
| CA (1) | CA2874919A1 (https=) |
| IN (1) | IN2014DN10214A (https=) |
| MX (1) | MX2014014657A (https=) |
| WO (1) | WO2013178815A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20050389A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| UA107562C2 (uk) | 2008-12-05 | 2015-01-26 | Спосіб лікування псоріазу | |
| WO2010091894A2 (en) | 2009-02-16 | 2010-08-19 | Giuliani International Limited | Methods of treating hair related conditions |
| CN109999017A (zh) | 2012-02-09 | 2019-07-12 | 诺格拉制药有限公司 | 治疗纤维化的方法 |
| CN104284655B (zh) | 2012-04-18 | 2017-10-27 | 诺格拉制药有限公司 | 治疗乳糖不耐受的方法 |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| CA3010615C (en) | 2016-01-14 | 2024-02-20 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
| MX2020010155A (es) * | 2018-03-27 | 2021-03-25 | Univ Texas | Compuestos de ox2r. |
| EP4495101A3 (en) | 2019-02-08 | 2025-04-30 | Nogra Pharma Limited | Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof |
| CR20220565A (es) | 2020-05-06 | 2023-01-13 | Merck Sharp & Dohme Llc | Inhibidores de il4i1 y métodos de uso |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003105779A2 (en) * | 2002-06-17 | 2003-12-24 | Taktix Corporation | Guanidine compounds as anesthetics and for treatment of nervous system disorders |
| WO2007084728A2 (en) * | 2006-01-19 | 2007-07-26 | Abbott Laboratories | 2-imino-benzimidazoles |
| WO2008036244A1 (en) * | 2006-09-18 | 2008-03-27 | The Burham Institute For Medical Research | Use of cyclosporin a to sensitize resistant cancer cells to death receptor ligands |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1069385A1 (ru) * | 1982-05-07 | 1990-11-15 | Научно-исследовательский институт фармакологии АМН СССР | Бромид 2-амино-3-(1-адамантилкарбонилметил)-1-( @ -пиперидино-этил)-бензимидазоли , обладающий способностью угнетать иммунитет |
| CA2601458C (en) * | 2005-03-15 | 2011-04-26 | Pfizer Inc. | Benzimidazolone derivatives as cb2 receptor ligands |
| EP1926734A1 (en) * | 2005-08-22 | 2008-06-04 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
| HRP20191953T8 (hr) * | 2008-03-07 | 2021-06-25 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | DERIVATI 1-BENZIL-3-HIDROKSIMETILINDAZOLA I NJIHOVA UPORABA U LIJEČENJU BOLESTI KOJE SE BAZIRAJU NA EKSPRESIJI MCP-1, CX3CR1 i P40 |
| EP2262777B8 (en) * | 2008-03-07 | 2016-05-04 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1 |
-
2013
- 2013-05-31 EP EP13726005.5A patent/EP2861563B1/en not_active Not-in-force
- 2013-05-31 CN CN201380033704.2A patent/CN104619687A/zh active Pending
- 2013-05-31 MX MX2014014657A patent/MX2014014657A/es unknown
- 2013-05-31 US US14/404,838 patent/US20150126553A1/en not_active Abandoned
- 2013-05-31 JP JP2015514534A patent/JP2015521195A/ja active Pending
- 2013-05-31 CA CA 2874919 patent/CA2874919A1/en not_active Abandoned
- 2013-05-31 IN IN10214DEN2014 patent/IN2014DN10214A/en unknown
- 2013-05-31 KR KR20147036702A patent/KR20150016377A/ko not_active Withdrawn
- 2013-05-31 AU AU2013269550A patent/AU2013269550A1/en not_active Abandoned
- 2013-05-31 WO PCT/EP2013/061328 patent/WO2013178815A1/en not_active Ceased
- 2013-05-31 BR BR112014030039A patent/BR112014030039A2/pt not_active IP Right Cessation
-
2016
- 2016-12-14 US US15/378,672 patent/US20170183313A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003105779A2 (en) * | 2002-06-17 | 2003-12-24 | Taktix Corporation | Guanidine compounds as anesthetics and for treatment of nervous system disorders |
| WO2007084728A2 (en) * | 2006-01-19 | 2007-07-26 | Abbott Laboratories | 2-imino-benzimidazoles |
| WO2008036244A1 (en) * | 2006-09-18 | 2008-03-27 | The Burham Institute For Medical Research | Use of cyclosporin a to sensitize resistant cancer cells to death receptor ligands |
Non-Patent Citations (3)
| Title |
|---|
| GEORGINA A. HOLLOWAY,ET AL.: "Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 * |
| MARTIN E. HAYES,ET AL.: "Lead identification of 2-iminobenzimidazole antagonists of the chemokine receptor CXCR3", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 * |
| RAJENDRA N.VERMA，ET AL.: "Synthesis of 5-methoxy-1,3-disubstituted-benzimidazolin-2-thiones as potential biologically active agents", 《JOURNAL OF THE INDIAN CHEMICAL SOCIETY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013269550A1 (en) | 2014-12-18 |
| US20170183313A1 (en) | 2017-06-29 |
| KR20150016377A (ko) | 2015-02-11 |
| JP2015521195A (ja) | 2015-07-27 |
| WO2013178815A1 (en) | 2013-12-05 |
| MX2014014657A (es) | 2015-08-10 |
| US20150126553A1 (en) | 2015-05-07 |
| IN2014DN10214A (https=) | 2015-08-07 |
| EP2861563A1 (en) | 2015-04-22 |
| BR112014030039A2 (pt) | 2017-06-27 |
| EP2861563B1 (en) | 2017-07-12 |
| CA2874919A1 (en) | 2013-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104619691B (zh) | 能够调节t-细胞应答的杂环及其使用方法 | |
| CN104619687A (zh) | 能够调节t-细胞应答的双环杂环及其使用方法 | |
| US12110292B2 (en) | Ligands to cereblon (CRBN) | |
| US9926299B2 (en) | Inhibitors of bruton's tyrosine kinase | |
| US11730726B2 (en) | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | |
| EP3263564B1 (en) | Aza-aryl 1h-pyrazol-1-yl benzene sulfonamides as ccr(9) antagonists | |
| KR20160079082A (ko) | 오토탁신 억제제 화합물 | |
| MX2010010619A (es) | Moduladores de quimioquina. | |
| BR112020019399A2 (pt) | Compostos macrocíclicos como inibidores de trk quinases | |
| WO2018214796A1 (zh) | 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途 | |
| KR101905295B1 (ko) | 나프티리딘디온 유도체 | |
| CN115803085A (zh) | 新型细胞代谢调节化合物及用途 | |
| CA3207475A1 (en) | Quinoxaline derivatives and uses thereof | |
| KR100845770B1 (ko) | 피라졸로디아제핀계 화합물 및 그의 제조방법 | |
| WO2025255109A1 (en) | Combination of a chromene derivative tcr inhibitor and a pde4 inhibitor | |
| RU2775505C2 (ru) | Изохинолин-3-иловые карбоксамиды и их получение и применение | |
| BR112017004868B1 (pt) | Derivados de pirrolopirimidina como antagonistas do receptor nmda nr2b e composição farmacêutica que os compreende |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20180622 |